‹ ›
MYP_066247
← PREVIOUS NEXT → BACK
Basic Information
SFTI-polyR-L2
Anticancer
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
15 amino acids
C77H144N32O18S2
Standard
Sequence
CTKSIPPICRRKRRR
Physicochemical Analysis
1870.30 Da
11.84
6.74
6.50
0.4492
-1.40
0.64
-0.82
178.28
52.00
0.0000
0.00
125.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
855.14
-9.90
35.0
27.0
63.0
129.0
2.0
14.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0112647 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anticancer
PC-3
100 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0114693 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anticancer Cytotoxic
HUVEC
100 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0267955 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anticancer
MCF-7
41.84±0.07 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0306547 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anticancer
Human red blood cells: no hemolytic activity(as show in Fig.4)
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0387542 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anticancer
HT-29
100 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/